Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR donor T-lymphocyte infusion after haploidentical CD34-selected HSCT in hematologic malignancies
2012-004461-41Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Mar 2013
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ATIR101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more, sponsored by Kiadis Pharma. Primary endpoint: Transplant-related mortality. Started Mar 2013; status: completed.
02
Drugs
ATIR101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)hematopoietic malignancies
Beyond the preview
Go deeper on 2012-004461-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004461-41.